Skip To Main Content
Ruolan Wu on Muck Rack

Ruolan Wu

As seen in: Wiley Online Library, PLOS ONE, Frontiers, Frontiers in Immunology, MDPI, The McGill Daily
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ruolan

Contact Ruolan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Zhenwu Decoction Alleviates Renal Fibrosis by Disrupting the Bidirectional Crosstalk Between TGF-β/Smad and Notch Signaling

|
By Ruolan Wu, Fugen Li, Meiqi Hong
| Wiley Online Library Verified
1 Introduction Chronic kidney disease (CKD) and its progression to end-stage renal disease constitute a major public health challenge, attributable to their high prevalence, elevated mortality rates, significant healthcare costs, and limited public awareness (Fletcher et al. 2022; Francis et al. 2024; Kalantar-Zadeh et al. 2021).
Open in Who Shared Issue with article?

Correction: Impact of diets high in trans-fatty acids on cardiovascular diseases in adults aged 55 and older: insights from the Global Burden of Disease 2021 data

|
By Jishi Ye, Yu Xin Liu, Juan Ren, Ruolan Wu, Jingli Chen, Rong Xiang, Yifan Jia
| Frontiers
A Correction on Impact of diets high in trans-fatty acids on cardiovascular diseases in adults aged 55 and older: insights from the Global Burden of Disease 2021 data by Ye, J., Liu, Y., Ren, J., Wu, R., Chen, J., Xiang, R., and Jia, Y. (2026). Front. Nutr. 13:1681274. doi: 10.3389/fnut.2026.1681274 In the published article, there was a mistake in the author-affiliation linking.
Open in Who Shared Issue with article?

Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors

|
By Yingting Wei, Jing Niu, Jinghua Huang, Ruolan Wu, Kaiyan Gu, Anyue Wu, Lihua Qiu, Ruiju He
| Frontiers in Immunology
Abstract Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) have improved outcomes in ovarian cancer with homologous recombination deficiency (HRD). However, approximately half of high-grade serous ovarian cancers retain intact homologous recombination repair and are classified as homologous recombination–proficient (HRP), limiting the clinical benefit of PARPi in this population.
Open in Who Shared Issue with article?
See all 6 licensed articles (8 Total)